Glutamate transporter SLC1A6 promotes resistance to immunotherapy in cancer

Glutamate transporter SLC1A6 promotes resistance to immunotherapy in cancer

Abstract Background Resistance to immune checkpoint inhibitors remains a significant challenge in the treatment of cancer. Emerging evidence suggests that metabolic reprogramming plays a crucial role in tumor metabolism and progression. Our study strived to investigate the role and underlying mechan...

Full description

Saved in:
Bibliographic Details
Main Authors: Chenchen Li, Yi Lin, Haoran Zheng, Hengda Zeng, Longhao Xu, Daqin Wu, Jianwen Lao, Peicong Cai, Shuai Liang, Chunhui Wang, Tianxin Lin, Wenlong Zhong
Format: Article
Language:English
Published: Springer 2025-06-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Cancer treatment
SLC1A6
Immunotherapy
T cells
Online Access:https://doi.org/10.1007/s00262-025-04074-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04074-4

Similar Items